It is no secret that Tryp Therapeutics (CNSX: TRYP) (OTCMKTS: TRYPF) has been gearing for a busy clinical trial schedule in 2021. The company is expected to initiate at least two Phase 2a trials this calendar year and up to six more by the second half of next year. Included in the effort to formulate the best possible trial design possible is the inclusion of Fluence Training, an organization of researchers and psychotherapists which offers training and provider services in psychedelic integration and psychedelic-assisted therapy. TDR interviewed Chief Executive Officer, Co-Founder and Lead Trainer, Dr. Ingmar Gorman, to explain more of what Fluence Training’s is all about.
Tryp Therapeutics originally announced a master service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp’s clinical trial activities. The collaboration will initially focus on supporting Tryp’s Phase 2a clinical trial for eating disorders with Jennifer Miller, M.D., at the University of Florida. Fluence will consult on the design of psychotherapy protocols for the treatment and will provide extensive training for the therapists that will be conducting the trial.
As we learned from Dr. Gorman, finding the right trial partner on the psychedelic therapy side of the equation is no easy task.
My role with Tryp is a little bit different. We were brought in as experts—we have expertise on the psychotherapy side of delivering, or… psychotherapy side about a drug trial that’s going through the FDA process or research and review and potentially approval. So, how are we selected? Well, I think it comes from pretty much what I alluded to which is that there are not many people in the world—or companies for that matter—that have put together this expertise in psychotherapy of these novel compounds, as well as the experience.
As Dr. Gorman rightfully states, the importance of getting the properly-trained practitioners in place is a critical component to any assisted-therapy trial program. The psychedelic substances being used are extremely powerful and psychoactive, have a long duration of action, and are applied to patients in deep emotional distress. Having improperly trained therapists could serve to adversely skew endpoint data, which could spell disaster for the sponsoring company.
Which is why Tryp Therapeutics sought to partner with acknowledged leaders in the industry—Fluence Training. Both company Co-Founders not only have the requisite educational credentials, but have been Co-Principal Investigators and therapist for an FDA approved Phase 3 clinical trial previously (MDMA, PTSD).
Click on the embedded image to see more of our inaugural interview with Dr. Ingmar Gorman, In his own words.